Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.1%

9 terminated/withdrawn out of 56 trials

Success Rate

83.9%

-2.6% vs industry average

Late-Stage Pipeline

30%

17 trials in Phase 3/4

Results Transparency

72%

34 of 47 completed trials have results

Key Signals

34 with results8 terminated

Enrollment Performance

Analytics

Phase 1
19(35.2%)
Phase 2
17(31.5%)
Phase 3
15(27.8%)
Phase 4
2(3.7%)
N/A
1(1.9%)
54Total
Phase 1(19)
Phase 2(17)
Phase 3(15)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (56)

Showing 20 of 56 trials
NCT05859802Phase 2Completed

Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis

Role: collaborator

NCT01839279Phase 2Completed

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

Role: lead

NCT01337986Phase 2Completed

Ampyra for Optic Neuritis in Multiple Sclerosis

Role: collaborator

NCT00041717Phase 3Completed

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

Role: lead

NCT00641511Phase 2Withdrawn

Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)

Role: collaborator

NCT02242487Phase 3Completed

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Role: lead

NCT03887884Phase 1Completed

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Role: lead

NCT02240030Phase 3Completed

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Role: lead

NCT02352363Phase 3Completed

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Role: lead

NCT03051607Phase 3Terminated

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Role: collaborator

NCT02258152Phase 2Completed

SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

Role: collaborator

NCT02422940Phase 3Terminated

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

Role: lead

NCT01750684Phase 2Terminated

AC105 in Patients With Acute Traumatic Spinal Cord Injury

Role: lead

NCT01356940Phase 4Completed

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Role: collaborator

NCT02474407Phase 2Terminated

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

Role: lead

NCT00127530Phase 3Completed

Study of Oral Fampridine-SR in Multiple Sclerosis

Role: lead

NCT02398461Phase 1Completed

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Role: lead

NCT03200080Phase 1Terminated

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Role: collaborator

NCT01777555Phase 2Completed

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

Role: lead

NCT02316847Phase 2Terminated

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Role: lead